Skip to content

Clinical study of Esketamine for improving depressive symptoms in patients with lung cancer after smoking cessation

Clinical study of Esketamine for improving depressive symptoms in patients with lung cancer after smoking cessation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068591
Enrollment
Unknown
Registered
2023-02-24
Start date
2023-02-24
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression after quitting smoking

Interventions

Control group:An equal amount of saline is sprayed through the nose
Test group:Esketamine 0.5mg/kg

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Both male and female, aged from 18 to 65 years,Lung cancer is diagnosed, surgery for lung cancer is indicated; (2) ASA is classified as grade I~II;(3)Smoking history, 20 per day for 5 years;(4)Hamilton Depression Scale score (HDRS-24) < 35;(5)Voluntarily participate in this treatment and agree to sign the informed consent for relevant treatment.

Exclusion criteria

Exclusion criteria: (1) a history of serious physical or mental illness; (2) Serious risk of elevated blood pressure or intracranial pressure; (3) Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic/diastolic blood pressure exceeding 180/100 MMHG); (4) previous allergy to esketamine; (5) Unable to understand the content of relevant scales; (6) Pregnant women and women trying to get pregnant; (7) Untreated or undertreated patients with hyperthyroidism(8)Patients with severe arrhythmias (tachycardia, ventriculartachycardia, ventricular premature); (9)Subjects who have adverse risk factors deemed unsuitable for the study by the investigator;(10)Subjects who did not want to quit smoking during the trial.

Design outcomes

Primary

MeasureTime frame
HDRS-24;MADRS;CADSS;BPRS;

Secondary

MeasureTime frame
VAS-D;QIDS-SR16;adverse event;

Countries

China

Contacts

Public ContactWenyuan Wang

Zhejiang Provincial People's Hospital

Neuro-anesth@hotmail.com13588083716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026